MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • White Papers
  • DeviceTalks
Home » Penumbra, Sixense launch VR JV MVI Health

Penumbra, Sixense launch VR JV MVI Health

January 4, 2018 By Fink Densford Leave a Comment

Share

Penumbra, Sixense

Penumbra (NYSE:PEN) said today it inked a deal with Sixense Enterprises to launch the new virtual reality healthcare joint venture MVI Health.

The new JV will be headquartered in Alameda, Cali., and will be headed by Penumbra CEO Adam Elsesser. Penumbra will support the company with investments while Sixense will suport it through licensing, intellectual property and other resource contributions.

“We are excited about the potential of the Sixense technology and its ability to improve patient experiences across broad areas of healthcare and wellness. We look forward to collaborating with healthcare professionals and institutions to address a wide variety of medical conditions that can impact a vast number of people,” Penumbra and MVI Health CEO Elsesser said in a press release.

The companies have not yet released any detailed information on what specific devices or technology platforms that MVI Health will aim to develop.

“We have long believed in the tremendous potential of immersive, full-presence virtual reality to help improve lives though better healthcare and Penumbra is the perfect partner for us to collaborate with in this vision. We believe that by combining our unique immersive computing platform with Penumbra’s innovative approach to development and commercialization of medical products, MVI Health can establish itself as a leading digital health platform,” Sixense founder & CEO Amir Rubin said in a prepared statement.

Last November, Penumbra reported third-quarter results that topped the consensus forecast on Wall Street and raised its sales outlook for the rest of the year, despite a nearly 100% profit slide.

Filed Under: Business/Financial News Tagged With: Penumbra Inc., sixense

In case you missed it

  • Abbott nabs CMS reimbursement for FreeStyle Libre continuous glucose monitor
  • Zimmer Biomet wins FDA nod for Sidus stem-free shoulder system
  • Penumbra, Sixense launch VR JV MVI Health
  • Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
  • Malaysian regulators extend moratorium to summer 2018 for qualifying medical device registrants
  • Sleep Apnea dev Invicta Medical raises $21m
  • Hologic wins CE Mark for MyoSure Manual
  • Gore launches FDA IDE Excluder conformable AAA endoprosthesis trial
  • Medical device companies need to worry more about liability: Here’s why
  • Glaukos seeks FDA IDE nod for iStent infinite trial
  • FDA issues Class I recall for select J&J Sterilmed Agilis steerable introducer sheaths
  • Tandem Diabetes Care launches manufacturing ops at new San Diego plant
  • InVivo to end Inspire trial despite meeting primary endpoint, plans new study
  • Why innovation isn’t the key for treating stroke
  • Egalet teams up with Valeant division to promote pain-relief nasal spray
  • Abbott gains on Morgan Stanley upgrade, touts MR conditional FDA labeling
  • BD shares get boost from CNBC’s Jim Cramer

RSS From Medical Design & Outsourcing

  • Malaysian regulators extend moratorium to summer 2018 for qualifying medical device registrants
    By Stewart Eisenhart, Emergo Group The Medical Device Authority (MDA), Malaysia’s medical device regulator, will extend a moratorium for companies that have registered for market access but not yet received approval so that they may continue selling in the country as their premarket reviews proceed. Get the full story here at the Emergo Group’s blog. […]
  • Medical device companies need to worry more about liability: Here’s why
    Mike Drues has a piece of advice he likes to repeat to clients of his medical device regulatory consulting business: Don’t fear FDA; fear the product liability attorneys. “You should fear the product liability attorneys because they could impose a heck of a lot more damage on a company than the FDA ever could. And by […]
  • Why innovation isn’t the key for treating stroke
    Technology and innovation are not the most important things we can do for stroke, according to Stacey Pugh, VP and general manager of the neurovascular unit at Medtronic. The most important thing that could happen for stroke is passing proper legislation about taking patients in emergency situations to comprehensive stroke centers for proper treatment, Pugh […]
  • These lab-grown blood vessel replacements could benefit dialysis patients
    University of Minnesota researchers have developed a blood vessel replacement made of biological materials in a lab. The lab-grown vessels have no living cells at implantation and could be used as a graft for kidney dialysis patients. The lab-engineered blood vessel replacement is the first non synthetic, decellularized graft that is repopulated with cells using […]
  • Medical Device Excise Tax set to return early this year
    By Stewart Eisenhart, Emergo Group Despite multi-year efforts to fully repeal the Medical Device Excise Tax (MDET) on device sales in the US, the tax appears set to come back into force in early 2018. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s […]
  • Webinar: The top medtech stories of 2017 – Jan. 30
    Tuesday, January 30, 2018 2:00pm ET / 11:00 PT     The medtech industry saw its transformation accelerate in 2017: Whether it’s the roster of largest companies, business models or the regulatory environment, times are a-changing. Competition is also heating up in areas including diabetes care and robotic surgery. MDO’s managing editor Chris Newmarker will […]
  • Report slams European Union’s high-risk medical device approvals rate
    A health economics and outcomes research group has concluded that the assessment for high-risk medical devices in the European Union is of low quality and needs improvement. The report appears in the December 2017 issue of Value in Health by ISPOR. The authors looked at 1,376 health technology assessment (HTA) reports filed between 2010 and 2015. […]
  • Victrex opens $13 million Polymer Innovation Center
    Victrex recently announced that it has opened its new $13 million Polymer Innovation Center in Thornton Cleveleys, U.K. to help accelerate innovation. Victrex currently makes high-performance polyaryletherketone (PAEK) as well as selected parts for gears and dental discs. In hopes of developing next-generation thermoplastic solutions, the new facility is fully-operational and is dedicated to research […]
  • Medical device startups: Here’s how you successfully plan
    The development of the product development plan is an evolutionary effort that continues through the life of the medical device project. Bill Betten, Betten Systems Solutions, and Tom Waddell, Waddell Group This is the second in a series of articles that will discuss the design of innovative products in the highly regulated medical environment.  The […]
  • FDA refines least burdensome guidance for medical device oversight
    Stewart Eisenhart, Emergo Group Medical device regulators at the Food and Drug Administration have updated guidance clarifying what Least Burdensome Provisions mean for US market registrants. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MedicalDesignandOutsourcing.com […]
  • The medical device tax is back in effect
    The ringing in of the new year also rang in the return of the medical device tax, a 2.3% levy on medtech sales that went back into effect after a two-year pause. The U.S. Congress closed out 2017 without taking action to delay or repeal the medtech tax, despite broad support from both sides of the […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Connect with us on Google PlusGoogle+

Copyright © 2018 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy